ARCHIVES

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: What’s In A Name? DRCCA Doesn’t Do It; O’Conor Says ICRDB Program Should Consider New Challenges

October 3, 1980

House Passes 2.8 Percent Increase For NCI

December 11, 2009

Advocacy: NCCS, ASCO Petition FDA To Set Standards For Expanded Access Programs.

April 14, 2006

BRCA2 Carriers Reduced BC Risk By Prophylactic Surgery

June 30, 2006

NIH Expands Minority Biomedical Research Training

July 11, 1975

In Congress: Could NCI Make Use Of Increase? Porter Asks; “We Can Handle It Well,” Klausner Replies

April 3, 1998